There is considerable overlap between the effector pathways of SEMA3C and KRAS; both lead to PI3K/AKT and Raf/MEK/ERK activation and SEMA3C expression positively correlates with KRAS mutations in The Cancer Genome Atlas (TCGA) datasets of pancreatic adenocarcinoma [108,109]. The gene discussed is SEMA3C; the disease is pancreatic adenocarcinoma.